AYTU BIOPHARMA INC (AYTU) Stock Price, Quote, News and Overview
NASDAQ:AYTU - Nasdaq - US0547548588 - Common Stock - Currency: USD
AYTU Quote, Performance and Key Statistics
NASDAQ:AYTU (2/21/2025, 8:02:32 PM)
1.35
-0.03 (-2.17%)
The current stock price of AYTU is 1.35 USD. In the past month the price decreased by -19.16%. In the past year, price decreased by -53.92%.
AYTU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About AYTU
Company Profile
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 99 full-time employees. The company went IPO on 2017-10-20. The firm's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Company Info
AYTU BIOPHARMA INC
7900 E. Union Avenue, Suite 920
Denver COLORADO 80112 US
CEO: Joshua R. Disbrow
Employees: 102
Company Website: https://aytubio.com/
Investor Relations: http://www.irdirect.net/AYTU
Phone: 17204376580
AYTU BIOPHARMA INC / AYTU FAQ
What is the stock price of AYTU BIOPHARMA INC today?
The current stock price of AYTU is 1.35 USD. The price decreased by -2.17% in the last trading session.
What is the ticker symbol for AYTU BIOPHARMA INC stock?
The exchange symbol of AYTU BIOPHARMA INC is AYTU and it is listed on the Nasdaq exchange.
On which exchange is AYTU stock listed?
AYTU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AYTU BIOPHARMA INC stock?
7 analysts have analysed AYTU and the average price target is 8.16 USD. This implies a price increase of 504.44% is expected in the next year compared to the current price of 1.35. Check the AYTU BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AYTU BIOPHARMA INC worth?
AYTU BIOPHARMA INC (AYTU) has a market capitalization of 8.30M USD. This makes AYTU a Nano Cap stock.
How many employees does AYTU BIOPHARMA INC have?
AYTU BIOPHARMA INC (AYTU) currently has 102 employees.
What are the support and resistance levels for AYTU BIOPHARMA INC (AYTU) stock?
AYTU BIOPHARMA INC (AYTU) has a resistance level at 1.4. Check the full technical report for a detailed analysis of AYTU support and resistance levels.
Is AYTU BIOPHARMA INC (AYTU) expected to grow?
The Revenue of AYTU BIOPHARMA INC (AYTU) is expected to decline by -17.49% in the next year. Check the estimates tab for more information on the AYTU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AYTU BIOPHARMA INC (AYTU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AYTU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AYTU, evaluating the profitability, health, valuation and growth aspects
- AYTU BIOPHARMA INC (AYTU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AYTU BIOPHARMA INC (AYTU) Sales and EPS estimates to see what analysts future expectations are.
- AYTU BIOPHARMA INC (AYTU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AYTU BIOPHARMA INC (AYTU) Insider and Institutional Ownership to learn about the owners and their transactions.
- AYTU BIOPHARMA INC (AYTU) Stock Chart to make your own analysis
- AYTU BIOPHARMA INC (AYTU) Latest news and press-releases to stay up to date.
Does AYTU BIOPHARMA INC (AYTU) stock pay dividends?
AYTU does not pay a dividend.
When does AYTU BIOPHARMA INC (AYTU) report earnings?
AYTU BIOPHARMA INC (AYTU) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of AYTU BIOPHARMA INC (AYTU)?
AYTU BIOPHARMA INC (AYTU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
What is the Short Interest ratio of AYTU BIOPHARMA INC (AYTU) stock?
The outstanding short interest for AYTU BIOPHARMA INC (AYTU) is 2.13% of its float. Check the ownership tab for more information on the AYTU short interest.
AYTU Technical Analysis
AYTU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AYTU. AYTU has a bad profitability rating. Also its financial health evaluation is rather negative.
AYTU Financial Highlights
Over the last trailing twelve months AYTU reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 71.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.51% | ||
| ROE | -17.04% | ||
| Debt/Equity | 0.45 |
AYTU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AYTU. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 125.68% and a revenue growth -17.49% for AYTU